Cargando…

Association between interleukin-22 genetic polymorphisms and bladder cancer risk

OBJECTIVE: The cytokine interleukin-22 (IL-22), which is produced by T cells and natural killer cells, is associated with tumorigenesis and tumor progression in cancers. However, the role of IL-22 in bladder cancer has not been investigated. MATERIALS AND METHODS: A prospective hospital-based case-c...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Tao, Wu, XiaoHou, Liu, JiaJi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602377/
https://www.ncbi.nlm.nih.gov/pubmed/26598081
http://dx.doi.org/10.6061/clinics/2015(10)05
_version_ 1782394708711964672
author Zhao, Tao
Wu, XiaoHou
Liu, JiaJi
author_facet Zhao, Tao
Wu, XiaoHou
Liu, JiaJi
author_sort Zhao, Tao
collection PubMed
description OBJECTIVE: The cytokine interleukin-22 (IL-22), which is produced by T cells and natural killer cells, is associated with tumorigenesis and tumor progression in cancers. However, the role of IL-22 in bladder cancer has not been investigated. MATERIALS AND METHODS: A prospective hospital-based case-control study comprising 210 patients with pathologically proven bladder cancer and 210 age- and gender-matched healthy controls was conducted. The genotypes of 3 common polymorphisms (-429 C/T, +1046 T/A and +1995 A/C) of the IL-22 gene were determined with fluorogenic 5' exonuclease assays. RESULTS: Patients with bladder cancer had a significantly higher frequency of the IL-22 -429 TT genotype [odds ratio (OR)=2.04, 95% confidence interval (CI)=1.19, 3.49; p=0.009] and -429 T allele (OR=1.42, 95% CI=1.08, 1.87; p=0.01) than the healthy controls. These findings were still significant after a Bonferroni correction. When stratifying according to the stage of bladder cancer, we found that patients with superficial bladder cancer had a significantly lower frequency of the IL-22 -429 TT genotype (OR=0.48, 95% CI=0.23, 0.98; p=0.04). When stratifying according to the grade and histological type of bladder cancer, we found no statistical association. The IL-22 +1046 T/A and IL-22 +1995 A/C gene polymorphisms were not associated with the risk of bladder cancer. CONCLUSION: To the authors' knowledge, this is the first report documenting that the IL-22 -429 C/T gene polymorphism is associated with bladder cancer risk. Additional studies are required to confirm this finding.
format Online
Article
Text
id pubmed-4602377
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
record_format MEDLINE/PubMed
spelling pubmed-46023772015-12-07 Association between interleukin-22 genetic polymorphisms and bladder cancer risk Zhao, Tao Wu, XiaoHou Liu, JiaJi Clinics (Sao Paulo) Clinical Science OBJECTIVE: The cytokine interleukin-22 (IL-22), which is produced by T cells and natural killer cells, is associated with tumorigenesis and tumor progression in cancers. However, the role of IL-22 in bladder cancer has not been investigated. MATERIALS AND METHODS: A prospective hospital-based case-control study comprising 210 patients with pathologically proven bladder cancer and 210 age- and gender-matched healthy controls was conducted. The genotypes of 3 common polymorphisms (-429 C/T, +1046 T/A and +1995 A/C) of the IL-22 gene were determined with fluorogenic 5' exonuclease assays. RESULTS: Patients with bladder cancer had a significantly higher frequency of the IL-22 -429 TT genotype [odds ratio (OR)=2.04, 95% confidence interval (CI)=1.19, 3.49; p=0.009] and -429 T allele (OR=1.42, 95% CI=1.08, 1.87; p=0.01) than the healthy controls. These findings were still significant after a Bonferroni correction. When stratifying according to the stage of bladder cancer, we found that patients with superficial bladder cancer had a significantly lower frequency of the IL-22 -429 TT genotype (OR=0.48, 95% CI=0.23, 0.98; p=0.04). When stratifying according to the grade and histological type of bladder cancer, we found no statistical association. The IL-22 +1046 T/A and IL-22 +1995 A/C gene polymorphisms were not associated with the risk of bladder cancer. CONCLUSION: To the authors' knowledge, this is the first report documenting that the IL-22 -429 C/T gene polymorphism is associated with bladder cancer risk. Additional studies are required to confirm this finding. Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo 2015-10 2015-10 /pmc/articles/PMC4602377/ /pubmed/26598081 http://dx.doi.org/10.6061/clinics/2015(10)05 Text en Copyright © 2015 CLINICS http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Clinical Science
Zhao, Tao
Wu, XiaoHou
Liu, JiaJi
Association between interleukin-22 genetic polymorphisms and bladder cancer risk
title Association between interleukin-22 genetic polymorphisms and bladder cancer risk
title_full Association between interleukin-22 genetic polymorphisms and bladder cancer risk
title_fullStr Association between interleukin-22 genetic polymorphisms and bladder cancer risk
title_full_unstemmed Association between interleukin-22 genetic polymorphisms and bladder cancer risk
title_short Association between interleukin-22 genetic polymorphisms and bladder cancer risk
title_sort association between interleukin-22 genetic polymorphisms and bladder cancer risk
topic Clinical Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4602377/
https://www.ncbi.nlm.nih.gov/pubmed/26598081
http://dx.doi.org/10.6061/clinics/2015(10)05
work_keys_str_mv AT zhaotao associationbetweeninterleukin22geneticpolymorphismsandbladdercancerrisk
AT wuxiaohou associationbetweeninterleukin22geneticpolymorphismsandbladdercancerrisk
AT liujiaji associationbetweeninterleukin22geneticpolymorphismsandbladdercancerrisk